BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure by Özçelik, Serhat et al.
401
Original paper
O
R
IG
IN
A
L
 P
A
P
E
R
BRAF V600E mutation in papillary thyroid cancer 
is correlated with adverse clinicopathological features 
but not with iodine exposure
Serhat Özçelik1, Rifat Bircan2, Şükran Sarıkaya3, Aylin E. Gul3, Büşra Aydın2, Melike Özçelik4, 
Mehmet Çelik1, Akın Dayan1, Yasemin Tütüncü1, Hasret  Cengiz1, Nimet Karadayı3, Hülya Ilıksu Gözü5
1Endocrinology and Metabolism Section, Haydarpaşa Education and Training Hospital, Istanbul, Turkey
2Department of Molecular Biology & Genetics, Arts and Sciences Faculty, Namık Kemal University, Tekirdağ, Turkey 
3Department of Pathology, Kartal Dr. Lütfi Kırdar Education and Training Hospital, Istanbul, Turkey
4Department of Medical Oncology, Kartal Dr. Lütfi Kırdar Education and Training Hospital, Istanbul, Turkey
5Department of Endocrinology and Metabolism, Marmara University, School of Medicine, Istanbul, Turkey
Abstract 
Introduction: BRAFV600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. 
We aimed to evaluate the association between BRAFV600E mutation and well-established prognostic clinicopathological characteristics as 
well as iodine exposure.
Material and methods: From 2000 to 2012, the data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and Research Hospital in 
Turkey were reviewed retrospectively. Clinicopathological parameters were collected. BRAFV600E mutation was analysed by DNA sequenc-
ing method in tumour specimens. We hypothesised that BRAFV600E mutation prevalence is positively correlated with prolonged iodine 
exposure and expected to be higher in the second half of the recruitment period due to the increment in time spent from the iodisation 
process of the table salt in our country. Thus, iodine exposure was categorised as short-term (2000–2006) and long-term (2006–2012).
Results: A total of 197 patients were accrued. The study population predominantly consisted of conventional variant. A statistically 
significant relationship was observed between BRAFV600E mutation presence and age (p = 0.03), conventional variant PTC (p = 0.00002), 
T4 stage (p = 0.002), vascular invasion (p = 0.036), thyroid capsule invasion (p < 0.00001), extrathyroidal tissue invasion (p < 0.00001), and 
lymph node metastasis (p < 0.00001). When categorised as long-term and short-term, iodine exposure was not statistically significantly 
related with BRAFV600E mutation; however, there were far more PTC cases in the long-term group (86.3% vs. 13.7%).
Conclusion: We revealed that BRAFV600E mutation is associated with adverse clinicopathological parameters. There appeared to be no 
relation between long-term iodine exposure and BRAFV600E. (Endokrynol Pol 2019; 70 (5): 401–408)
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Introduction
Thyroid carcinoma is the most frequent type of endo-
crine-borne malignancies. Papillary thyroid carcinoma 
(PTC) and follicular thyroid carcinoma (FTC), which 
are derived from follicular cells and C-cell-derived 
medullary thyroid carcinoma, are the common sub-
types. Anaplastic type is the rarest variant and is highly 
aggressive [1].
Differentiated thyroid carcinomas, PTC and FTC, 
are slow-growing cancers. Early-stage disease can be 
treated successfully with surgical excision. Patients with 
disseminated disease eventually die from their cancer, 
although the majority survive for years, which is an un-
common circumstance for many other advanced-stage 
malignancies. 
An understanding of thyroid cancer pathogenesis 
remains critical for the prevention of the disease occur-
rence and for the development of targeted therapies 
directed against the causative pathway in the care of 
patients with advanced disease. Contributory genetic 
abnormalities have been defined to cause different sub-
types of thyroid cancer. Frequent genetic abnormalities 
associated with PTC are the BRAF activating mutations, 
fusion oncogene RET/PTC, and NTRK rearrange-
ments. BRAFV600E activating mutation, which occurs 
in 29-83% of tumours, is the most common mutation 
in PTC. BRAF is the downstream target of RAS in the 
mitogen-activated protein kinase (MAPK) signalling 
pathway. Following activation, RAF interacts with MEK 
and initiates phosphorylation of ERK kinase leading its 
activation. Activated ERK mediates the transcription 
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our country. Thus, iodine exposure was categorised as short-term 
(2000–2006) and long-term (2006–2012).
Method
DNA Isolation
Genomic DNA was extracted from 8-10 μm sections of formalin-
fixed and paraffin-embedded (FFPE) PTC tissue samples, starting 
with deparaffinisation using conventional xylene/ethanol treat-
ment, one-hour incubation with proteinase K, and subsequent DNA 
purification utilising the QIAampDNA FFPE tissue kit (Qiagen, 
USA) according to the manufacturer’s instructions. Following the 
DNA isolation, DNA were archived at –20°C in a freezer until the 
start of the study.
PCR and DNA sequencing
In order to detect the mutations at exon 15 of the BRAF gene, PCR 
was performed with the following forward and reverse primers as 
described by Qu K. et al. (2013): BRAF 15F, 5’-CCTAAACTCTTCATA-
ATGCTTGCT-3’; and BRAF15R, 5’-AGTAACTCAGCAGCATCT-
CAGG-3’ [12].
Briefly, PCR was performed in a 50 mL volume containing 50 to 
100 ng of genomic DNA; 20 pmol/L forward and 20 pmol/L reverse 
primers; HotStarTaq Master Mix (Qiagen, USA) including HotStar-
Taq DNA Polymerase (2.5 U), PCR Buffer (with 1.5 mM MgCl2), and 
200 μM each dNTP in final reaction volume. The PCR amplification 
was carried out in a Proflex thermocycler (ABI, USA) under the 
following conditions: one cycle at 95°C for 15 minutes; 40 cycles at 
94°C for 30 seconds, 56°C for 30 seconds, and 72°C for 30 seconds; 
and a final extension step at 72°C for 10 minutes. Amplified PCR 
products were purified by using the PEG precipitation method as 
described by Rosenthal et al. (1993) [13]. The purified PCR products 
were sequenced utilising DTCS quick start kit (Beckman Coulter, 
USA). The sequencing reaction was carried out in a Proflex ther-
mocycler at 96°C for 20 s, 50°C for 20 s, and 60°C for four minutes, 
according to the manufacturer’s manual. Sequence analysis was 
performed on the automatic DNA sequencer (Beckman Coulter 
Genome Lab GeXP Genetic Analysis System, USA). DNA sequences 
and chromatograms obtained were examined by using the Genome 
Lab GeXP Genetic Analysis System Version 10.2 DNA sequencing 
program (Beckman Coulter, USA).
Statistical analysis
All statistical analyses were carried out using SPSS 17.0 version (IBM 
Corp., Armonk, NY, USA). Characteristics of patients were evalu-
ated with descriptive analysis. Chi-squared test and Fisher’s exact 
test were used in order to compare the clinicopathological features 
as well as the iodine exposure status, between BRAFV600E-positive 
and -negative subgroups. P values below 0.05 were accepted as 
statistically significant. 
of many genes, which promotes cellular growth and 
survival [2–5].
Radiation exposure and iodine excess are the 
best-known predisposing factors for the development 
of PTC [6, 7]. There is some evidence that high iodine 
exposure may be a driver event for transforming 
BRAF to a constitutively active state [7]. In Turkey, 
iodisation of table salt was practised in 1999 and fully 
carried out in 2002 [8–10]. Duration of time from the 
iodisation process may be an indirect measure of 
iodine exposure. 
Extensive data suggest that BRAFV600E mutation is 
associated with a poorer prognosis compared to PTC 
without harbouring the BRAFV600E mutation. It appears 
to be associated with increased risk of extrathyroidal 
tumour extension, lymph node metastases, and recur-
rence [7]. In this study, we aimed to describe the relation 
of iodine exposure, if any, as well as the clinicopatho-
logical factors with BRAFV600E mutation.
Material and methods
Study oversight
This study was conducted in compliance with the ethical principles 
according to the Declaration of Helsinki, and it was approved by 
the local Institutional Review Board (April 8, 2014). Data of PTC 
patients admitted to Dr. Lutfi Kirdar Kartal Education and Research 
Hospital were reviewed retrospectively. A total of 197 patients (159 
females and 38 males; median age 46, range 17–86 years) with PTC 
were screened for BRAFV600E mutation in this study from October 
2000 to October 2012. Other clinicopathological features including 
PTC variant, tumour size, T stage, necrosis, calcification, vascular 
invasion, tumour capsule status and invasion, extrathyroidal inva-
sion, multicentricity, and concomitant pathology in thyroid tissue 
were collected.
Trials conducted in an effort to define the iodine status in the Turkish 
population, with the use of urinary iodine excretion, are presented 
in Table I. Urinary iodine excretion was not evaluated in our study. 
Using the national studies as the basis for the iodine status of the 
study population, we principally aimed to look for the concept 
of relative increment in iodine exposure [8-11]. We hypothesised that 
BRAFV600E mutation prevalence is positively correlated with increas-
ing iodine exposure and is expected to be higher in the second 
half of the recruitment period (2006 to 2012) due to the increment 
in exposure time spent from the iodisation process of table salt in 
Table I. An overview of the iodine status screening trials in the Turkish population
Screening size Study population (number) Median UIC [μg/L] 
1997–1999 National (20 regions) 5.948 36 μg/L 
2002* National (20 regions) 4.128 53 μg/L 
2002** National (10 regions) 7.006 87,5 μg/L 
2002*** National (30 regions) 11.134 75 μg/L 
2007**** National (30 regions) 2.280 130 μg/L 
*Follow-up studies of 1997–99 screening in 2002 (same 20 regions); **10 new regions screened in 2002 with unknown previous status; ***Total results of all 2002 
screening (30 regions); ****Follow-up studies of 2002 screening in 2007; UIC — urinary iodine concentrations
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Results
Patient characteristics
A total of 197 patients with PTC were screened for 
BRAFV600E mutation in this study. Characteristics of 
patients are summarised in Table II. Conventional vari-
ant (57.4%) was the predominant variant, followed by 
follicular (33.5%) and oncocytic (9.1%) variants. Tumour 
size ranged from 0.1 to 8 cm with a median size of 0.9 
cm. Microcarcinoma slightly dominated the samples 
with a ratio of 53.6%. According to the eighth pTNM 
staging, 118 patients (60.1%) had T1, 31 patients (15.7%) 
T2, 27 patients (13.7%) T3, and 21 patients (10.5%) had 
T4 tumours. Extratumoural thyroid tissue consisted 
of diffuse hyperplasia (30.4%), nodular adenomatous 
hyperplasia (24.3%), nodular hyperplasia (19.8%), lym-
phocytic thyroiditis (17.8%), and multinodular adeno-
matous hyperplasia (14.7%) with decreasing frequency. 
One or more condition/s might have been seen in one 
extratumoural tissue sample. Most of the tumours were 
limited to thyroid tissue, with only 17.7% having extra-
thyroidal tissue invasion and 7.6% exhibiting lymph 
node metastasis. Of 35 patients with extrathyroidal 
tissue invasion, 14 (40%) had minor and 21 (60%) had 
gross spread. While calcification status (45.2% present, 
54.8% absent) was almost evenly shared by samples, 
the presence of necrosis (1.5%) and vascular invasion 
(5.1%) were considerably low.
BRAFV600E mutation 
BRAFV600E mutation frequency was found to be 22.8% 
(45/197) in this study. Association of BRAFV600E mutation 
with clinical and pathological parameters is detailed 
in Table III. A statistically significant relationship was 
observed between BRAFV600E mutation presence and 
conventional variant PTC (p = 0.00002), T4 stage 
(p = 0.002), vascular invasion (p = 0.036), thyroid 
capsule invasion (p < 0.00001), extrathyroidal tissue 
invasion (p < 0.00001), and lymph node metastasis 
(p < 0.00001). Age, for the cut-off level, 45 (7th TNM), 
was not significantly associated with BRAFV600E mutation 
whereas age, for the cut-off level of 55 (8th TMN), was 
significantly associated with mutation status (p = 0.03). 
The extratumoural thyroid background, tumour ne-
crosis and capsule formation were not significantly 
associated with BRAFV600E mutation. When grouped in 
two, iodine exposure, was not statistically significantly 
related with BRAFV600E mutation; however, there were 
more PTC cases in the long-term group compared to 
short-term (86.3% vs. 13.7%).
Rare BRAF mutations 
Along with BRAFV600E mutation, BRAFF583Y, BRAFF595L, 
and BRAFV600V were also detected in the study group. 
Table II. Clinicopathological features of patients
N (%)
Age
≤ 55 147 (74.6%)
> 55 50 (25.4%)
Gender
Female 159 (80.7%)
Male 38 (19.3%)
PTC variants
Conventional 113 (57.4%)
Follicular 66 (33.5%)
Oncocytic 18 (9.1%)
T stage
T1 118 (60.1%)
T2 31 (15.7%)
T3 27 (13.7%)
T4 21 (10.5%)
Tumour size
Microcarcinoma 109 (55.3%)
Macrocarcinoma 88 (44.7%)
Necrosis
Present 3 (1.5%)
Absent 194 (98.5%)
Calcification
Present 89 (45.2%)
Absent 108 (54.8%)
Vascular invasion
Present 10 (5.1%)
Absent 187 (94.9%)
Capsule formation
Present 89 (45.2%)
Absent 108 (54.8%)
Tumour capsule 
invasion
Present 44 (22.3%)
Absent 153 (77.7%)
Thyroid capsule 
invasion
Present 40 (20.3%)
Absent 157 (79.7%)
Extrathyroidal 
tissue invasion
Present 35 (17.7%)
Absent 162 (82.3%)
Multicentricity
Present 33 (16.8%)
Absent 164 (83.2%)
Lymph node 
metastasis
Present 15 (7.6%)
Absent 182 (92.4%)
Extratumoural 
thyroid tissue*
Lymphocytic 
thyroiditis 35 (17.8%)
Diffuse hyperplasia 60 (30.4%)
Nodular hyperplasia 39 (19.8%)
Nodular adenomatous 
hyperplasia 48 (24.3%)
Multinodular 
adenomatous 
hyperplasia
29 (14.7%)
BRAFV600E
Wild 152 (77,2%)
Mutant 45 (22.8%)
Iodine exposure
Short-term 27 (13.7%)
Long-term 170 (86.3%)
*One or more condition might have been seen in one extratumoural tissue 
sample; PTC — papillary thyroid carcinoma
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Table III. Association of BRAFV600E mutation with other clinicopathological characteristics
Wild  
n (%)
Mutant 
n (%) p
Gender 0.318
Female 125 (78.6%) 34 (21.4%)
Male 27 (71.1%) 11 (28.9%)
PTC variants 0.00002
Conventional 74 (65.5%) 39 (34.5%)
Follicular 63 (95.5%) 3 (4.5%)
Oncocytic 15 (83.3%) 3 (16.7%)
Tumour size 0.183
Microcarcinoma 88 (80.7%) 21 (19.3%)
Macrocarcinoma 64 (72.7%) 24 (27.3%)  
T stage 0.002
T1 100 (84.7%) 18 (15.3%)
T2 27 (87.1%) 4 (12.9%)
T3 14 (51.8%) 13 (48.2%)
T4 11 (52.3%) 10 (47.7%)  
Vascular invasion 0.036
Present 5 (50.0%) 5 (50.0%)
Absent 147 (78.6%) 40 (21.4)  
Multicentricity 0.506
Present 24 (72.7%) 9 (23.7%)
Absent 128 (78%) 36 (22%)  
Extrathyroidal extension < 0.00001
Present 14 (40.0%) 21 (60.0%)
Absent 138 (85.2%) 24 (14.8%)  
Calcification 0.211
Present 65 (73.0%) 24 (27.0%)
Absent 87 (80.6%) 21 (19.4%)  
Thyroid capsule invasion < 0.00001
Present 16 (40%) 24 (60%)
Absent 136 (86.6%) 21 (13.4%)  
Lymph node metastasis < 0.00001
Present 2 (13.3%) 13 (86.7%)
Absent 150 (82.4%) 32 (17.6%)  
Age 0.03
≤ 55 119 (81.0%) 28 (19.0%)
> 55 33 (66.0%) 17 (34.0%)  
Thyroid background 0.217
Lymphocytic thyroiditis 28 (80.0%) 7 (20.0%)
Diffuse hyperplasia 41 (68.3%) 19 (31.7%)
Nodular hyperplasia 30 (76.9%) 9 (21.3%)  
Nodular adenomatous hyperplasia 42 (87.5%) 6 (12.5%)
Multinodular adenomatous hyperplasia 22 (75.9%) 7 (24.1%)
Iodine exposure 0.059
Short-term 17 (63.0%) 10 (37.0%)
Long-term 135 (79.4%) 35 (20.6%)  
PTC — papillary thyroid carcinoma
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The BRAFF583Y was found in four conventional variants 
of PTC. Tumours with BRAFF83Y mutation were macro-
carcinomas, all of which had thyroid capsule invasion, 
soft tissue invasion, and lymph node metastasis. The 
identified BRAFF595L mutation in the oncocytic variant 
of PTC was a macrocarcinoma with thyroid capsule 
and soft tissue invasion. Lastly, the BRAF V600V mutation 
was estimated as one in each of the conventional, fol-
licular, and oncocytic variants (Fig. 1). Regarding this 
mutation arising from three different PTC variants, the 
conventional one was microcarcinoma whereas fol-
licular and oncocytic variants were noted as macrocar-
cinoma (Tab. IV). All these mutations were previously 
reported, and they were not directly associated with 
the constitutive activation of the BRAF protein. But it is 
reported that BRAF F595L mutation is a gain-of-function 
variant with intermediate activity that does not act para-
doxically, but cooperates with mutant RAS to promote 
oncogenic signalling [14, 15].
Discussion
Papillary thyroid carcinoma is the most frequently 
encountered malignant thyroid tumour. Although cu-
Table 4. Rare BRAF mutations
BRAFF583Y Variants of PTC Tumour size [cm] Thyroid capsule invasion Soft tissue invasion
Lymph node 
metastasis
Patient 1 Conventional 1.5 + + +
Patient 2 Conventional 1.4 + + +
Patient 3 Conventional 1.1 + + +
Patient 4 Conventional 2.5 + + +
BRAFF595L
Patient 1 Oncocytic 3.5 + + –
BRAFV600V
Patient 1 Conventional 0.6 – – –
Patient 2 Follicular 3.0 – – –
Patient 3 Oncocytic 3.5 + + –
PTC — papillary thyroid carcinoma
Figure 1. Detected mutations at exon 15 of the BRAF gene. A. tttÆtat exchange at codon 583 (BRAFF583Y mutation); B. tttÆctt exchange 
at codon 595 (BRAFF595L mutation); C. gtgÆgag exchange at codon 600 (BRAFV600E mutation); D. gtgÆgag exchange at codon 600 
(BRAFV600V mutation). Arrows indicate localisation of the mutations
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rative treatment options for advanced disease are still 
lacking, rapid progress has been made over the years in 
understanding the molecular mechanisms underlying 
PTC tumorigenesis and progression. Among the genetic 
abnormalities, activating BRAFV600E in the mitogen acti-
vated protein kinase pathway is the most commonly ob-
served mutation, with a prevalence of 29–83% [2–5]. In 
the current study, we evaluated the BRAFV600E mutation 
prevalence and its association with clinicopathological 
characteristics and a potential environmental causative 
agent of BRAF V600E, iodine exposure.
The presence of BRAFV600E mutation portends a worse 
prognosis in many series [16–18]. In an analysis of 314 
patients, those with a BRAFV600E mutation had a signifi-
cantly worse outcome than did those with a wild-type 
BRAF [19]. Higher rates of recurrent and persistent 
disease were observed. Similarly, a recent metanalysis 
[16] involving 2247 patients found a higher likelihood of 
recurrent disease in BRAFV600E-positive patients. A retro-
spective multicentre study by Xing et al. revealed poorer 
recurrence-free survival in mutation-positive patients 
[20]. The impact of BRAFV600E mutation on survival could 
not be addressed in the present study because most of 
the patients were lost to follow-up. 
Despite the scant evidence on survival due to the 
necessity of longer follow-up time, abundant data is 
available regarding clinicopathological factors and 
BRAFV600E relation. Xing et al., in their review, reported 
that BRAFV600E was associated with extrathyroidal inva-
sion, lymph node metastasis, and advanced surgical 
stage [21]. Our findings, in addition to these three 
parameters that have been confirmed to be poor prog-
nostic by almost all studies, indicate that conventional 
variant and vascular invasion were positively associ-
ated with BRAFV600E mutation. The specific histological 
variant being a high-risk feature was compatible with 
the results of Lee et al., who reported that BRAFV600E 
mutation was most frequent in tall-cell followed by con-
ventional variant [22]. There were no tall cell variants 
in the present study. However, follicular and oncocytic 
variants existed and had lower frequencies of mutation 
than the conventional variant. In accordance with our 
findings, Smith et al., in their analysis investigating 
whether mutation rates differ between conventional 
versus follicular variant, found that BRAFV600E mutation 
is significantly more common in conventional variant 
PTC [23]. Another study by Nikiforova et al. came to 
same conclusion, finding an impact of BRAFV600E on the 
incidence of unfavourable prognostic factors including 
classic and tall cell variant histology and advanced stage 
[24]. The authors also noted that older age was corre-
lated with mutation positivity. Likewise, > 45 years of 
age at diagnosis was shown to have close association 
with BRAFV600E in the study by Lu et al. [25]. On the other 
hand, the current study failed to show the same, but, 
adjusting the cut-off level to 55 years according to the 
current TNM staging, our results were also consistent 
with the previous studies. Older age at diagnosis (> 
55) was correlated with BRAFV600E mutation presence.  
In a recent study from China, 1032 patients were 
evaluated. The authors ended up with 54.6% BRAFV600E 
mutation, which was significantly associated with extra-
thyroidal extension and advanced TNM stage [7]. They 
also concluded that thyroid background of Hashimoto 
thyroiditis (HT) and lymphocytic thyroiditis (LT) were 
negatively correlated with mutation presence. Lim et 
al., by a single-centre experience with 3130 cases, re-
ported a similar result, observing that PTC with a back-
ground of LT was significantly lower in those with the 
BRAFV600E mutation compared with those with wild-type 
BRAF [26]. In another study exploring BRAFV600E muta-
tion as a predictor for central nodal metastasis, HT 
emerged as an independent protective factor. In the 
current study we found no significant association with 
thyroid background and BRAFV600E mutation. However, 
the frequency of BRAFV600E mutation was remarkably 
low (22.8%) compared to both previous reports [27] 
and the above-mentioned data, in which mutation 
rates were 54.6%, 74.3%, and 75.3%, respectively. The 
difference might be attributable to the diverse histologi-
cal variant composition across the studies. The current 
study involved 34.5% of follicular variant PTC. A study 
by Navarro et al., involving a much lower percentage 
of follicular variants (4.6%) than our study, identified 
a relatively low ratio of BRAFV600E mutations (38.4%) 
compared to existing literature [28]. Another possible 
explanation for this could be the heterogeneity in select-
ed populations and the mutation analysis techniques. 
In a study conducted in the Irish population, the 
prevalence of BRAFV600E mutation, compared to the 
RET/ PTC mutation in PTC, was higher than previously, 
and the authors suspected that this might be due to 
an environmental factor [29]. At least some data sug-
gest potential association with high iodine intake and 
BRAFV600E. The available data are conflicting, with some 
suggesting positive and others negative or no relation. 
In the first study analysing iodine status in Turkey 
conducted from 1997 through 1999, median urinary 
iodine concentration of the various regions was noted 
as 36 μg/L; the follow-up study, in 2007, evaluated the 
performance of the iodisation of table salt and showed 
that the median urinary iodine amount increased to 
130 μg/L. Considering these data as a guide, our study, 
undertaken between 2000 and 2012, did not address the 
urinary iodine concentration, but aimed at looking for 
the impact of “relative increment in iodine exposure” 
on BRAF mutation. We defined the exposure as the 
time spent from the iodisation process of table salt in 
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our country and dichotomised into short-term and 
long-term, according to whether the PTC was diag-
nosed in the first or second half of the study period. The 
trials had different designs on defining iodine exposure. 
In one study, the authors compared the prevalence of 
the BRAFV600E mutation in classical PTC of 1032 patients 
from five regions in China that harbour different iodine 
content in natural drinking water [7]. They argued that 
high iodine intake may be a risk factor for PTC because 
the prevalence of BRAFV600E mutation was significantly 
higher in regions with high iodine content than any of 
the regions with normal iodine content. Contrary to this 
finding, in the present study, there was no significant 
association between long-term iodine exposure and 
BRAFV600E. However, the iodine content of drinking 
water in the previous trial was far above the amount 
used for prophylaxis in table salt. Additionally, the au-
thors speculated that the worldwide increment in the 
frequency of PTC is the consequence of rising iodine 
support, but this should be interpreted cautiously. 
More extensive utility of thyroid ultrasonography and 
fine-needle aspiration biopsy compared to previous 
years may have an effect on the rise in incidence. In 
support of this, we experienced far more PTC cases in 
the second half of our study period. 
On the other hand, investigators at Harvard Medi-
cal School noted that, on exposure with excess iodine, 
rat thyroid follicular cells that conditionally express 
BRAFV600E  showed a decrease in BRAFV600E-induced 
up-regulation of miR-17-92, blocking NOTCH signal-
ling, which confers proliferative advantage. Overall, 
this study shows that high iodine exerts a protective 
influence overBRAFV600E-activated thyroid cells. Iodine 
might reduce acute BRAFV600E oncogene induction and 
activity [30]. Frasca et al. recently examined the relation-
ship of BRAFV600E mutation in PTC with iodine intake in 
some regions in Italy. The authors found BRAFV600Emu-
tation in 107 of 270 cases in an iodine-sufficient region 
(40%) vs. 18 of 53 cases of PTC in an iodine-deficient 
region (34%), which was, similarly to our study, statisti-
cally insignificant [31].
This study had some features that might be viewed 
as potential weaknesses. First, selection bias might have 
been introduced due to the retrospective nature of the 
study. Second, follow-up data do not exist, thus we are 
unable to comment on whether the findings translate 
into outcome measures. Lastly, the sample size is small. 
Conclusion
The results of our retrospective study provide evidence 
suggesting that BRAFV600E mutation is correlated with 
unfavourable prognostic features. The results also 
challenge existing assumptions about the high iodine 
exposure and BRAF mutation incidence, demonstrating 
no association.
Acknowledgements 
This work was supported by a grant of the Research 
Fund of the Tekirdağ Namık Kemal University (Project 
number: NKUBAP.01.YL.16.021).
References
1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer 
Data Base report on 53,856 cases of thyroid carcinoma treated in 
the U.S., 1985–1995. Cancer. 1998; 83(12): 2638–2648, indexed in 
Pubmed: 9874472.
2. Tallini G, Asa SL. RET oncogene activation in papillary thyroid carcino-
ma. Adv Anat Pathol. 2001; 8(6): 345–354, indexed in Pubmed: 11707626.
3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in hu-
man cancer. Nature. 2002; 417(6892): 949–954, doi: 10.1038/nature00766, 
indexed in Pubmed: 12068308.
4. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid car-
cinoma. J Natl Cancer Inst. 2003; 95(8): 625–627, doi: 10.1093/jnci/95.8.625, 
indexed in Pubmed: 12697856.
5. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene muta-
tion in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer 
Res. 2003; 63(15): 4561–4567, indexed in Pubmed: 12907632.
6. Suzuki K, Mitsutake N, Saenko V, et al. Radiation signatures in child-
hood thyroid cancers after the Chernobyl accident: possible roles 
of radiation in carcinogenesis. Cancer Sci. 2015; 106(2): 127–133, 
doi: 10.1111/cas.12583, indexed in Pubmed: 25483826.
7. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the 
T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol 
Metab. 2009; 94(5): 1612–1617, doi:  10.1210/jc.2008-2390, indexed in 
Pubmed: 19190105.
8. Erdoğan G, Erdogan MF, Emral R. Iodine status and goiter prevalence 
in Turkey before mandatory iodinization. J Endocrinol Invest. 2002; 
25(3): 224–228, doi: 10.1007/BF03343994, indexed in Pubmed: 11936463 .
9. Erdoğan MF, Ağbaht K, Altunsu T, et al. Current iodine status in Turkey. J 
Endocrinol Invest. 2009; 32(7): 617–622, doi: 10.1007/BF03346519, indexed 
in Pubmed: 19564718.
10. Hacettepe University Instute of Population Studies Ministry of Health. 
Turkey Demographic and Health Survey Iodization of table salts. Turkey, 
Ankara 2003: 145–147.
11. Gozu HI, Bircan R, Krohn K, et al. Similar prevalence of somatic TSH 
receptor and Gsalpha mutations in toxic thyroid nodules in geographical 
regions with different iodine supply in Turkey. Eur J Endocrinol. 2006; 
155(4): 535–545, doi: 10.1530/eje.1.02253, indexed in Pubmed: 16990652.
12. Qu K, Pan Q, Zhang Xi, et al. Detection of BRAF V600 mutations 
in metastatic melanoma: comparison of the Cobas 4800 and Sanger 
sequencing assays. J Mol Diagn. 2013; 15(6): 790–795, doi:  10.1016/j.
jmoldx.2013.07.003, indexed in Pubmed: 23994118.
13. Rosenthal A, Coutelle O, Craxton M. Large-scale production of DNA 
sequencing templates by microtitre format PCR. Nucleic Acids Res. 1993; 
21(1): 173–174, doi: 10.1093/nar/21.1.173, indexed in Pubmed: 8441614.
14. Kordes M, Röring M, Heining C, et al. Cooperation of BRAF(F595L) 
and mutant HRAS in histiocytic sarcoma provides new insights 
into oncogenic BRAF signaling. Leukemia. 2016; 30(4): 937–946, 
doi: 10.1038/leu.2015.319, indexed in Pubmed: 26582644.
15. Park JiH, Kwon HJu, Park CS, et al. Anaplastic Transformation of Papil-
lary Thyroid Carcinoma in a Young Man: A Case Study with Immuno-
histochemical and BRAF Analysis. Korean J Pathol. 2014; 48(3): 234–240, 
doi: 10.4132/KoreanJPathol.2014.48.3.234, indexed in Pubmed: 25013423.
16. Russo M, Malandrino P, Nicolosi ML, et al. The BRAF(V600E) mutation 
influences the short- and medium-term outcomes of classic papillary 
thyroid cancer, but is not an independent predictor of unfavorable 
outcome. Thyroid. 2014; 24(8): 1267–1274, doi:  10.1089/thy.2013.0675, 
indexed in Pubmed: 24787545.
17. Guerra A, Fugazzola L, Marotta V, et al. A high percentage of BRAFV600E 
alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin 
Endocrinol Metab. 2012; 97(7): 2333–2340, doi:  10.1210/jc.2011-3106, 
indexed in Pubmed: 22508706.
18. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF 
V600E mutation and mortality in patients with papillary thyroid cancer. 
JAMA. 2013; 309(14): 1493–1501, doi: 10.1001/jama.2013.3190, indexed in 
Pubmed: 23571588.
19. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic 
value of BRAF mutation in thyroid cancer. Ann Surg. 2007; 246(3): 
466–70; discussion 470, doi:  10.1097/SLA.0b013e318148563d, indexed 
in Pubmed: 17717450.
408
O
R
IG
IN
A
L
 P
A
P
E
R
BRAF V600E mutation in papillary thyroid cancer Serhat Özçelik et al.
20. Chen Y, Sadow PM, Suh H, et al. BRAF(V600E) Is Correlated with 
Recurrence of Papillary Thyroid Microcarcinoma: A Systematic 
Review, Multi-Institutional Primary Data Analysis, and Meta-Analy-
sis. Thyroid. 2016; 26(2): 248–255, doi:  10.1089/thy.2015.0391, indexed 
in Pubmed: 26671072.
21. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E 
mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015; 
33(1): 42–50, doi: 10.1200/JCO.2014.56.8253, indexed in Pubmed: 25332244.
22. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF 
V600E mutation in papillary carcinomas of the thyroid: a meta-anal-
ysis. Cancer. 2007; 110(1): 38–46, doi:  10.1002/cncr.22754, indexed in 
Pubmed: 17520704.
23. Smith RA, Salajegheh A, Weinstein S, et al. Correlation between BRAF 
mutation and the clinicopathological parameters in papillary thyroid 
carcinoma with particular reference to follicular variant. Hum Pathol. 
2011; 42(4): 500–506, doi:  10.1016/j.humpath.2009.09.023, indexed in 
Pubmed: 21167555.
24. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid 
tumors are restricted to papillary carcinomas and anaplastic or poorly 
differentiated carcinomas arising from papillary carcinomas. J Clin 
Endocrinol Metab. 2003; 88(11): 5399–5404, doi: 10.1210/jc.2003-030838, 
indexed in Pubmed: 14602780.
25. Lu H, Qiu T, Ying J, et al. [Correlation between BRAF V600E muta-
tion and clinicopathologic features of papillary thyroid carcinoma]. 
Zhonghua Bing Li Xue Za Zhi. 2014; 43(12): 794–798, indexed in 
Pubmed: 25623974.
26. Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of 
the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup 
analysis of 3130 cases in a single center. Thyroid. 2013; 23(11): 1423–1430, 
doi: 10.1089/thy.2013.0036, indexed in Pubmed: 23496275.
27. Lang BH, Chai YJ, Cowling BJ, et al. Is BRAFV600E mutation a marker 
for central nodal metastasis in small papillary thyroid carcinoma? Endocr 
Relat Cancer. 2014; 21(2): 285–295, doi: 10.1530/ERC-13-0291, indexed in 
Pubmed: 24402044.
28. Navarro-Locsin CG, Chang AMV, Daroy ML, et al. Clinical and histo-
pathological profile of BRAF V600E mutation in conventional papillary 
thyroid carcinoma in a Filipino population. Malays J Pathol. 2016; 38(2): 
141–148, indexed in Pubmed: 27568671.
29. Smyth P, Finn S, Cahill S, et al. ret/PTC and BRAF act as distinct molecular, 
time-dependant triggers in a sporadic Irish cohort of papillary thyroid 
carcinoma. Int J Surg Pathol. 2005; 13(1): 1–8, doi: 10.1177/10668969050
1300101, indexed in Pubmed: 15735849.
30. Daniell K, Nucera C. Effect of the micronutrient iodine in thyroid 
carcinoma angiogenesis. Aging (Albany NY). 2016; 8(12): 3180–3184, 
doi: 10.18632/aging.101143, indexed in Pubmed: 27997357.
31. Frasca F, Nucera C, Pellegriti G, et al. BRAF(V600E) mutation and the 
biology of papillary thyroid cancer. Endocr Relat Cancer. 2008; 15(1): 
191–205, doi: 10.1677/ERC-07-0212, indexed in Pubmed: 18310287.
